PRECISION MEDICINE STUDY:
PROMISING EARLY RESULTS
In 2016, the MMRF launched the Molecular Profiling
Protocol. This precision medicine study aimed to
sequence the DNA of 500 myeloma patients in the
hopes of identifying DNA changes that could be
targets for new treatments. (genetic) information is crucial to getting each
patient the correct treatment for their exact
disease. The early results from this study suggest
that approaching treatment through precision
medicine holds great promise.
In the last year, 291 patients have participated in
the study. Seventy-six percent of study participants
were found to have DNA changes that are good
candidates for new treatments. Results from this
study will be presented at the 2017 American
Society of Hematology meeting in Atlanta, Georgia,
this December by Daniel Auclair, PhD, Senior VP of
Research at MMRF. To tap into this potential, MMRF has launched
clinical trials for patients with specific mutations
and is planning more innovative, efficient clinical
trial designs to test multiple treatments for specific
populations of patients simultaneously under the
same clinical protocol! This new format will allow
for faster trial start-up and enrollment, which will
accelerate new treatments to patients.
Although more therapy choices are available than
ever before in myeloma, having precise DNA
“
The Molecular Profiling Protocol re-emphasizes that Precision Medicine approaches could
benefit a large number of myeloma patients. Application of these approaches in the clinic
has so far been limited because targeted agents are not widely available. We hope to
remedy this by working closely with regulatory agencies and the myeloma community to
launch additional targeted trials.
”
— Daniel Auclair, PhD | Senior Vice President of Research MMRF
ACCEL E RATO R • W I N T E R 2017
7